Peginterferon and Dose-Titrated Ribavirin for Hepatitis C-Associated Nephrotic Membranoproliferative Glomerulonephritis Type 1
- 1 October 2005
- journal article
- case report
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 50 (10) , 1804-1806
- https://doi.org/10.1007/s10620-005-2941-x
Abstract
No abstract availableKeywords
This publication has 12 references indexed in Scilit:
- Diagnosis, management, and treatment of hepatitis C†Hepatology, 2004
- Dosage of Ribavirin in Patients With Hepatitis C Should Be Based on Renal Function: A Population Pharmacokinetic AnalysisTherapeutic Drug Monitoring, 2002
- Recurrent Glomerulonephritis and Risk of Renal Allograft LossNew England Journal of Medicine, 2002
- National Institutes of Health Consensus Development Conference Statement: Management of hepatitis C: 2002—June 10-12, 2002Hepatology, 2002
- National institutes of health consensus development conference statement: Management of hepatitis C: 2002 — June 10-12, 2002Hepatology, 2002
- Risk of Renal Allograft Loss from Recurrent GlomerulonephritisNew England Journal of Medicine, 2002
- Hepatitis C infection and the patient with end-stage renal diseaseHepatology, 2002
- Ribavirin treatment in dialysis patients with chronic hepatitis C virus infection – a pilot studyJournal of Viral Hepatitis, 2001
- Safety of interferon and ribavirin therapy in haemodialysis patients with chronic hepatitis C: results of a pilot studyNephrology Dialysis Transplantation, 2001
- RECOMBINANT LEUCOCYTE INTERFERON A INDUCES STEROID-RESISTANT ACUTE VASCULAR REJECTION EPISODES IN RENAL TRANSPLANT RECIPIENTSThe Lancet, 1984